© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Based on recent data, Y-mAbs Therapeutics, Inc. (YMAB) shows an Average True Range (ATR) of 0.09 and an Enterprise Value of 592.13M. Its average trading volume over the past 3 months is N/A, indicating liquidity. These fundamental metrics provide insight into YMAB's underlying financial health and market activity.
Y-mAbs Therapeutics, Inc. (YMAB) technical indicators as of December 23, 2025: the SMA 20 is 0.61%, SMA 50 at 25.84%, and SMA 200 at 40.75%. The RSI 14 value is 81.2, suggesting its current momentum. These technical analysis signals help assess YMAB's price trends and potential future movements.
Y-mAbs Therapeutics, Inc. (YMAB) stock performance overview as of December 23, 2025: The 52-week high is $8.62 (currently -46.55% below), and the 52-week low is $3.55 (currently 142.54% above). Over the past year, YMAB's performance is N/A, compared to the S&P 500's 10.56% change.
According to market data, Y-mAbs Therapeutics, Inc. (YMAB) stock's recent performance metrics show that over the last month, YMAB is 1.18%, with a Year-to-Date (YTD) performance of 9.96%. Over the past year, the stock has seen a N/A change. These figures summarize YMAB's price movements across various periods, reflecting its historical returns.
According to current financial data, YMAB stock's P/E (TTM) ratio is -17.56, which compares to the S&P 500's P/E of 32.59. The sector median P/E is -1.24. Key valuation ratios for YMAB, including P/S (4.58), P/B (4.46), and P/FCF (-21.83), offer insights into how the company is valued relative to its earnings, sales, book value, and free cash flow.